Eran Zahavy

Eran has nearly 20 years of leading positions in the R&D for Chemical and Biology Diagnostic in government research institutes and in In Vitro Diagnostic industry, holding more than 40 peer-reviewed scientific publications and patents. Eran had served as the Head of Innovation IIBR (Israel's Institution for Biologic Research) for the last 5 years including during the Covid pandemic crisis. In his capacity, he had led significant new collaborations, including the COVID-19 vaccine (BriLife) development and its license to NRx. He served as CTO at Israel's leading clean-tech incubator "Hutchison-Kinrot", CTO of TACount and as scientific advisor in Hutchison, Longliv fund and other startup companies. Eran holds a Ph.D. in Chemistry & Biophysics from the Hebrew University and a Post Doc from the University of TX, Austin. He has worked with Adaltis part-time in the last several years and joined full-time as CTO of the Bio-Division of BATM in October 2021.